SCHEDULE: Nikko Asset Management Discloses 5.4% Stake in 10x Genomics

Nikko Asset Management Americas, Inc. has disclosed a 5.4% beneficial ownership stake in 10x Genomics, Inc. Class A common stock.

Summary

• Nikko Asset Management Americas, Inc. reported beneficial ownership of 6,009,653 shares of 10x Genomics, Inc. Class A common stock.
• This ownership represents 5.4% of the Class A common stock outstanding.
• The reporting person, Nikko Asset Management Americas, Inc., is an investment adviser based in the United States.
• The shares are held with shared voting power over 5,605,769 shares and shared dispositive power over all 6,009,653 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of 10x Genomics, Inc.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing indicates an institutional investment firm, Nikko Asset Management Americas, Inc., has taken a significant stake in 10x Genomics, a company operating in the life sciences and biotechnology tools sector. Such disclosures can signal institutional confidence or strategic positioning within the industry.

Related Party Transactions

• Nikko Asset Management Americas, Inc. is a subsidiary of Sumitomo Mitsui Trust Group Inc. and Nikko Asset Management Co., Ltd. These parent entities may be deemed to beneficially own the reported securities.

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional stake can influence market perception and potentially provide a level of stability or interest in the stock.

Key Dates

Keywords

10x Genomics, Nikko Asset Management, Beneficial Ownership, Institutional Investment, Class A Common Stock, SEC Filing, Investment Adviser